MedTrace Logo

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

NCT03232112 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2021-06-04

No results posted yet for this study

Summary

The study is a double-blinded, randomized, placebo-controlled, 26-weeks clinical trial. The objective of the trial is to investigate the effects of the GLP-1 receptor agonist Bydureon® (exenatide) vs. placebo on alcohol intake in patients with a diagnosis of alcohol dependence.

Conditions

  • Alcohol Dependence, in Remission
  • Addiction, Alcohol

Interventions

DRUG

Exenatide 2 MG Injection

Subcutaneous injection once-weekly

DRUG

BD PosiFlush (saline)

Subcutaneous injection once-weekly

Sponsors & Collaborators

  • The Novavì outpatient clinics, Copenhagen

    collaborator UNKNOWN

  • Neurobiology Research Unit, Rigshospitalet, Copenhagen

    collaborator UNKNOWN

  • Section of Biostatistics University of Copenhagen, Copenhagen

    collaborator UNKNOWN

  • Anders Fink-Jensen, MD, DMSci

    lead OTHER

Principal Investigators

  • Signe W. Düring, MD · The Novavi outpatient clinics, Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-07
Primary Completion
2020-03-15
Completion
2020-10-05

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232112 on ClinicalTrials.gov